Results 21 to 30 of about 822 (144)

Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: Plausible role of NLRP3 inflammasome and NF- κB [PDF]

Iranian Journal of Basic Medical Sciences, 2022
Objective(s): Inflammation is the major progenitor of obesity and associated metabolic disorders. The current study investigated the modulatory role of saroglitazar on adipocyte dysfunction and associated inflammation in monosodium glutamate (MSG) obese ...
Sayima Nabi, Uma Bhandari, Syed Haque
doaj   +1 more source

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial

Journal of Lipid Research, 2022
Saroglitazar, being a dual PPAR-α/γ agonist, has shown beneficial effect in diabetic dyslipidemia and hypertriglyceridemia. Fibrates are commonly used to treat severe hypertriglyceridemia.
Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, Farheen. Shaikh, Pio Cruz-López   +4 more
doaj   +1 more source

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet

BMC Cancer, 2023
Background Saroglitazar is a novel PPAR-α/γ agonist with predominant PPAR-α activity. In various preclinical models, saroglitazar has been shown to prevent & reverse symptoms of NASH. In view of these observations, and the fact that NASH is a progressive
Suresh R. Giri, Bibhuti Bhoi, Chitrang Trivedi, Akshyaya Rath, Rohan Rathod, Anish Sharma, Ramchandra Ranvir, Shekhar Kadam, Kailash Ingale, Hiren Patel, Abraham Nyska, Mukul R. Jain   +11 more
doaj   +1 more source

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.

PLoS ONE, 2022
Background and objectiveSaroglitazar is a newer antidiabetic agent approved to manage dyslipidemia. The objective is tevaluate the efficacy and safety profiles of saroglitazar in patients with dyslipidemia.MethodsA systematic search was conducted using ...
Manik Chhabra, Kota Vidyasagar, Sai Krishna Gudi, Jatin Sharma, Rishabh Sharma, Muhammed Rashid   +5 more
doaj   +1 more source

Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is a commonly encountered problem which affects one third of the general population. Saroglitazar, a Peroxisome Proliferator Activated Receptor (PPAR) alpha α and gamma γ agonist has been ...
Akash Jaiswal, Kavita Jain, Amit Kumar Singh   +2 more
doaj   +1 more source

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

BMC Pharmacology and Toxicology, 2021
Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate ...
Rasoul Akbari, Tahereh Behdarvand, Reza Afarin, Hamid Yaghooti, Mohammad Taha Jalali, Narges Mohammadtaghvaei   +5 more
doaj   +1 more source

Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice

Heliyon, 2023
We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora cordifolia with Piper longum [TC + PL], Withania somnifera [WS], Glycyrrhiza glabra [GG], AYUSH–64 [AY-64], and Saroglitazar [S]) on various parameters in a diet ...
Deepika Kumari, Jyoti Gautam, Vipin Sharma, Sonu Kumar Gupta, Soumalya Sarkar, Pradipta Jana, Vikas Singhal, Prabhakar Babele, Parul Kamboj, Sneh Bajpai, Ruchi Tandon, Yashwant Kumar, Madhu Dikshit   +12 more
doaj   +1 more source

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Scientific Reports, 2020
Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD ...
Divya P. Kumar, Rebecca Caffrey, Jonathon Marioneaux, Prasanna K. Santhekadur, Madhavi Bhat, Cristina Alonso, Srinivas V. Koduru, Binu Philip, Mukul R. Jain, Suresh R. Giri, Pierre Bedossa, Arun J. Sanyal   +11 more
doaj   +1 more source

Long Term Safety and Efficacy of Saroglitazar in Indian Patients with Diabetic Dyslipidemia and Very High Triglyceride Levels: Real World Evidence

Clinical Diabetology, 2022
OBJECTIVE: Diabetes and diabetic dyslipidemia with high triglycerides (TGs) are commonly associated. Saroglitazar is the first dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia.
Arjun Baidya
doaj   +1 more source

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH. [PDF]

J Clin Exp Hepatol
Tavaglione F, Loomba R.
europepmc   +3 more sources